Ieq Capital LLC Acquires 3,826 Shares of Merck & Co., Inc. $MRK

Ieq Capital LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 0.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 803,040 shares of the company’s stock after purchasing an additional 3,826 shares during the period. Merck & Co., Inc. accounts for approximately 0.5% of Ieq Capital LLC’s holdings, making the stock its 29th largest holding. Ieq Capital LLC’s holdings in Merck & Co., Inc. were worth $116,690,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Round Rock Advisors LLC raised its position in Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after purchasing an additional 66 shares during the last quarter. Cypress Wealth Services LLC boosted its stake in shares of Merck & Co., Inc. by 0.5% during the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock valued at $1,960,000 after purchasing an additional 69 shares in the last quarter. Code Waechter LLC grew its holdings in shares of Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after purchasing an additional 71 shares during the last quarter. Quest 10 Wealth Builders Inc. grew its holdings in shares of Merck & Co., Inc. by 12.2% during the third quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock worth $102,000 after purchasing an additional 76 shares during the last quarter. Finally, Cascade Financial Partners LLC grew its holdings in shares of Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research reports. Freedom Broker raised their price objective on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a “hold” rating in a report on Monday, November 2nd. Cantor Fitzgerald boosted their target price on shares of Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. UBS Group upped their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Guggenheim raised their price target on shares of Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $155.74.

Check Out Our Latest Analysis on MRK

Insider Buying and Selling

In other news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares of the company’s stock, valued at $16,718,469.55. This trade represents a 34.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $137.75 on Thursday. Merck & Co., Inc. has a 12-month low of $93.90 and a 12-month high of $156.92. The business’s fifty day moving average is $145.73 and its 200 day moving average is $129.11. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. The stock has a market cap of $339.59 billion, a P/E ratio of 142.01, a P/E/G ratio of 6.57 and a beta of 0.13.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The firm had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the company earned $2.58 earnings per share. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.

Merck & Co., Inc. Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 2.6%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. The ex-dividend date is Tuesday, December 15th. Merck & Co., Inc.’s dividend payout ratio is 350.52%.

Top Merck & Co., Inc. Stories

These are some of the MRK stories that stood out recently:

  • Positive Sentiment: Merck and Isomorphic Labs will combine AI-based drug discovery with Merck’s research expertise to seek small-molecule candidates for an important oncology target. The collaboration could add to Merck’s future pipeline, though it is at an early discovery stage. Merck and Isomorphic Labs Enter Strategic Research Collaboration
  • Positive Sentiment: Recent pipeline updates include positive European regulatory opinions for expanded ENFLONSIA and WELIREG indications and Phase 2b results for efinopegdutide. These programs may help broaden growth beyond KEYTRUDA, although further development and regulatory steps remain. How Investors May Respond To Merck Pipeline Progress
  • Neutral Sentiment: Director Thomas H. Glocer plans to retire in May 2027, and Douglas M. Baker Jr. has been named independent lead director. The change appears to be a planned board transition, with no immediate business impact reported. Board Director Retirement and Appointment

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.